These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10837559)

  • 1. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies.
    Lin JH
    Adv Drug Deliv Rev; 1997 Sep; 27(2-3):215-233. PubMed ID: 10837559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
    Barry M; Gibbons S; Back D; Mulcahy F
    Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
    Plosker GL; Scott LJ
    Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
    Jarvis B; Faulds D
    Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saquinavir. Clinical pharmacology and efficacy.
    Vella S; Floridia M
    Clin Pharmacokinet; 1998 Mar; 34(3):189-201. PubMed ID: 9533981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
    Hsu A; Granneman GR; Bertz RJ
    Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
    Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
    Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
    Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.
    Remmel RP; Kawle SP; Weller D; Fletcher CV
    Clin Chem; 2000 Jan; 46(1):73-81. PubMed ID: 10620574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.
    Nannan Panday VR; Hoetelmans RM; van Heeswijk RP; Meenhorst PL; Inghels M; Mulder JW; Beijnen JH
    Cancer Chemother Pharmacol; 1999; 43(6):516-9. PubMed ID: 10321513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP; Plosker GL
    Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
    Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
    Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on HIV protease inhibitors.
    Vella S
    AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
    Shibata N; Gao W; Okamoto H; Kishida T; Iwasaki K; Yoshikawa Y; Takada K
    J Pharm Sci; 2002 Mar; 91(3):680-9. PubMed ID: 11920753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
    Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
    Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.